2025-12-28 - Analysis Report
Here's a comprehensive analysis of TMDX based on the provided data:

**1. Performance Relative to S&P 500 (VOO)**

*   **Company Overview:** TransMedics Group Inc is likely a medical technology company focused on organ preservation and transportation, based on the news and likely industry sector.
*   **TMDX Cumulative Return:** 205.68%
*   **VOO Cumulative Return:** 78.45%
*   **Divergence:** 138.1 (Relative Divergence: 66.1)
*   **Analysis:** TMDX has significantly outperformed the S&P 500 over the period represented by the cumulative returns. The divergence of 138.1 indicates a substantial difference in performance. The relative divergence of 66.1 suggests that the current divergence is in the mid-upper range of its historical fluctuation.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 126.0%  | 85.5% | 59.0%  | 0.3  | 4.2    |

*   **CAGR:** The Compound Annual Growth Rate fluctuates considerably. Recent years show strong growth (126-130%), while early periods showed stagnation or decline.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:** Alpha is generally positive, suggesting TMDX has outperformed its expected return based on its beta. Alpha dipped noticeably during 2023-2025 compared to the prior year.
*   **Beta:** Beta is low, indicating TMDX is less sensitive to market movements. However, Beta nearly tripled between 2022-2024 and 2023-2025, suggesting the stock's price movement is increasingly correlated with broader market volatility.
*   **Cap(B):** Market capitalization has grown substantially over the analyzed period, indicating company growth.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** $124.20
*   **Previous Close:** $126.99
*   **Change:** -$2.20
*   **5-day SMA:** 127.28
*   **20-day SMA:** 131.54
*   **60-day SMA:** 125.80

**Analysis:** The stock price is currently below its 5-day, 20-day, and slightly below the 60-day moving averages, suggesting a short-term downtrend. The recent drop of -$2.20 reinforces this.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 31.25 (Approaching Oversold)
*   **PPO:** -0.6598 (Negative, indicating potential downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** +0.6 (Short-term Increase)
*   **Expected Return:** 47.6% (Long-Term)

**Analysis:**

*   The high MRI suggests that, based on the model's parameters, TMDX is currently considered a good investment opportunity.
*   The RSI indicates the stock is nearing oversold territory, potentially signaling a buying opportunity for those who believe in the company's long-term prospects.
*   The negative PPO, combined with the recent price decline, suggests caution.
*   The Hybrid Signal suggests buying now with no cash reserve and investing a small percentage of the total investment monthly.
*   The positive change in recent divergence suggests a potential for short-term price increase.
*   The high expected return reinforces the MRI's investment recommendation.

**4. Recent News & Significant Events**

*   **Positive Headlines:** Several articles highlight TransMedics as a strong growth stock with significant upside potential (up to 150% by 2028).
*   **New Hires & Stock Options:** New hires receiving stock options and units are generally a positive sign, indicating confidence in the company's future and aligning employee incentives with long-term success.
*   **Insider Selling:**  The report of the CFO selling shares is a negative signal. However, the quantity (920 shares) needs to be considered in the context of the CFO's total holdings; a small sale might not be significant.
*   **Behavioral Patterns and Institutional Flows:** This suggests analysis of how institutions are trading the stock.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price:** $144.73 (Average)
*   **Analysis:** The strong buy consensus and average target price of $144.73 suggest that analysts are optimistic about TMDX's future performance, indicating roughly 16% upside from the current $124.2 price point.

**5. Comprehensive Analysis (Summary)**

TMDX has significantly outperformed the S&P 500, but it exhibits high volatility, as indicated by its large maximum drawdowns. Recent performance has been very strong, and analysts maintain a positive outlook. However, the recent price decline and negative PPO require careful consideration. The high MRI and expected return suggest that TMDX could be a worthwhile investment, particularly for investors with a long-term horizon who can tolerate high volatility. The news is largely positive, with analysts predicting substantial upside, but insider selling introduces a note of caution.

**Recommendation:**

Based on the information, a **cautiously optimistic** outlook for TMDX is warranted. The positive analyst ratings, strong growth projections, and favorable hybrid signal support a buy recommendation, particularly for long-term investors. However, the high volatility, recent price decline, negative PPO, and insider selling should be carefully considered. Monitor future price movements and news flow closely to make informed investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.